肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：依维莫司治疗原发性巨球蛋白血症多中心临床试验结果

2017-05-25 MedSci MedSci原创

原发性巨球蛋白血症依维莫司临床试验
关注

CLIN CANCER RES近期报道了一篇文章，报告依维莫司治疗原发性巨球蛋白血症多中心临床试验结果。

CLIN CANCER RES近期报道了一篇文章，报告依维莫司治疗原发性巨球蛋白血症多中心临床试验结果。

研究共纳入33例有症状且未接受过治疗的原发性巨球蛋白血症患者。依维莫司（10mg/d）治疗直至出现疾病进展或无法接受的毒性反应。在治疗过程中允许剂量降阶。在最佳反应情况下，血清平均IgM水平从4440mg/dl下降到1360mg/dl（P＜0.0001），平均血红蛋白由10.g/dL上升为12g/dL（P=0.001）。在连续活检的患者中，平均骨髓疾病负担由75%下降到52.5%。ORR及主要反应率分别为72.7%以及60.6%。在接受基因检测的患者中，无反应患者与野生型MYD88及CXCR4突变状态有关。平均反应时间为4周。血清IgM水平及骨髓疾病负担不一致性明显。平均随访时间13.1个月，所有患者平均病情进展时间为21个月，主要反应患者平均病情进展时间为33个月。7例患者依维莫司治疗中断导致血清IgM快速反弹，2例患者依维莫司治疗中断导致有症状的高粘血症。27%的患者因药物毒性导致治疗中断，其中18%为肺炎。

文章最后认为，依维莫司在未接受过治疗的原发性巨球蛋白血症中具有治疗活性。IgM不一致性常见，治疗中断常导致血清IgM快速反弹。未接受过治疗的患者与接受过治疗的患者相比肺炎更为常见。与原发性巨球蛋白血症其他治疗方式相比，依维莫司的风险及疗效应进行仔细的权衡。

原始出处：
Steven P.Treon,Kirsten Meid,et al.Propsective,Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia(WMCTG 09-214).CLIN CANCER RES.May 2017 doi:10.1158/1078-0432.CCR-16-1918

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2035142, encodeId=1c5b20351426d, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Jun 24 08:06:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903915, encodeId=5020190391535, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Apr 12 01:06:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846543, encodeId=2e2518465437d, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Jan 09 15:06:00 CST 2018, time=2018-01-09, status=1, ipAttribution=)]
    2017-06-24 xzw113

    #球蛋白#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2035142, encodeId=1c5b20351426d, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Jun 24 08:06:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903915, encodeId=5020190391535, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Apr 12 01:06:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846543, encodeId=2e2518465437d, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Jan 09 15:06:00 CST 2018, time=2018-01-09, status=1, ipAttribution=)]
    2018-04-12 luoxiaog

    #多中心#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2035142, encodeId=1c5b20351426d, content=<a href='/topic/show?id=5a426866eae' target=_blank style='color:#2F92EE;'>#球蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68667, encryptionId=5a426866eae, topicName=球蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2317301, createdName=xzw113, createdTime=Sat Jun 24 08:06:00 CST 2017, time=2017-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1903915, encodeId=5020190391535, content=<a href='/topic/show?id=7d454302945' target=_blank style='color:#2F92EE;'>#多中心#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43029, encryptionId=7d454302945, topicName=多中心)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02f5179, createdName=luoxiaog, createdTime=Thu Apr 12 01:06:00 CST 2018, time=2018-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1846543, encodeId=2e2518465437d, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Jan 09 15:06:00 CST 2018, time=2018-01-09, status=1, ipAttribution=)]
    2018-01-09 jiyangfei

    #原发性#

    0